Cartilage regeneration with cell therapy - current and future aspects

Time: To be announced
To be announced
Prof Anders Lindahl


Osteoarthritis (OA) is characterized by joint pain and impairment due to cartilage degradation and is one of the most common forms of musculo-skeletal disease in the world. The initiation of OA is unknown but age, obesity and trauma as well as genetic factors combined with low-grade inflammation play important roles. No early diagnostic biomarker is available and no disease modifying treatment exists except for autologous chondrocyte transplantation (ACT/ACI) developed by our group for treatment of focal cartilage defects. In this presentation the transition of the ACI technology from animal studies to an ATMP product over a 30 year period will be discussed as well the excellent long term clinical results. The challenges for future will be based on improvement of the ACT technology towards biological resurfacing. One such option could be the derivation of chondroprogenitor donor cell lines from induced pluripotent stem cell lines established from human cartilage (c-iPS cells) combined with automated cell culturing. Furthermore, the need of a deeper understanding of cartilage regeneration mechanisms and development of better diagnostic tools for early OA will be addressed.
To view the video assoicated with this lecture click here

Hosted By

The European Laboratory Research & Innovation Group Our Vision : To provide outstanding, leading edge knowledge to the life sciences community on an open access basis
Event Logo

Get the App

Get this event information on your mobile by
going to the appstore or google play and search for 'elrig'
Eventflo Home
copyright ELRIG,, Labhoo Ltd 2003-2021